Experiences with
Cyclophosphamide1,139 public posts
Should You Get the COVID-19 Vaccine During a Disease Flare-Up?
You should keep taking the following medications as prescribed:
Hydroxychloroquine (Plaquenil)
IVIG
Low-dose glucocorticoids (ex: prednisone, daily dose < 20 mg)
Sulfasalazine (Azulfidine)
Leflunomide (Arava)
Mycophenolate (CellCept)
Azathioprine (Imuran)
Cyclophosphamide (Cytoxan) (oral)
TNF biologics
Want to take advantage of all our features? Just log in!
or
7 Questions to Ask Your Rheumatologist If You’re Nervous About Getting the COVID-19 Vaccine
These medications include:
Methotrexate
JAK inhibitors (ex: Xeljanz, Olumiant, Rinvoq)
Abatacept (Orencia), injectable or IV form
Rituximab (Rituxan)
Cyclophosphamide infusion
Even if your doctor decides you should not taper off any of these medications, it’s still worth it to get the vaccine.
Getting a COVID-19 Vaccine with Autoimmune or Inflammatory Rheumatic Disease: New Guidance from the American College of Rheumatology
Cyclophosphamide infusion: Time administration so it’s one week after each COVID-19 vaccine dose
Other Recommendations for Before and After Getting a COVID-19 Vaccine
The guidance also includes these additional pointers to keep in mind for before and after getting the vaccine:
There’s no preference
NICE Recommends Acalabrutinib for treating CLL for certain groups
NICE has approved Acalabrutinib as monotherapy and is recommended as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, [u]BUT ONLY IF[/u]:
* there is a 17p deletion or TP53 mutation, or
* there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab
Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
approval is based on the Phase 3 ECOG1912 study (also referred to as E1912) that demonstrated newly diagnosed patients age 70 or younger (median age of 58) treated with IMBRUVICA® plus rituximab had significantly improved progression-free survival (PFS) compared to patients treated with fludarabine, cyclophosphamide
NICE Approves Acalabrutinib (Calquence) for specified groups of CLL patients in England
Thanks to Peggy4 for posting this yesterday, here's a bit more detail.
NICE has determined that Acalabrutinib will be available to CLL patients in the following groups:
* previously treated CLL patients.
*untreated patients with 17p deletion or TP53 mutations.
*untreated patients who are unsuitable